NCT07048613Active, not recruiting
Comparative Study of MRI and TU in Identifying Clinically Significant Prostate Cancer Among Ethnic Groups
Comparative Study of Magnetic Resonance Imaging and Transrectal Ultrasound in Identifying Clinically Significant Prostate Cancer Among Diverse Ethnic Groups Using Histopathology as the Gold Standard
Source: ClinicalTrials.gov · Last updated 2 Jul 2025
Brief summary (registry, in English)
This study is designed to compare the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Transrectal Ultrasound (TRUS) in detecting clinically significant prostate cancer, using histopathology (biopsy results) as the gold standard. Prostate cancer is a leading cause of cancer-related morbidity among men globally, and its detection often varies across ethnic groups due to genetic, environmental, and healthcare access factors. This research aims to evaluate how MRI and TRUS perform across diverse ethnic populations to determine the most reliable imaging modality for early diagnosis.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 120 (actual)
- First submitted
- 24 Jun 2025
- Start date
- 17 Mar 2025
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Superior University
- Diseases
- Prostate cancer
- NCT number
- NCT07048613
What you commit to
- Study type: Observational
- Participants enrolled: 120
- From 17 Mar 2025 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who have previously had treatment for prostate cancer, such as hormone therapy, chemotherapy, radiation, or surgery
Other illness
- Severe comorbidities that make safe imaging or biopsy impossible, such as severe heart failure or end-stage renal disease
Who the study is looking for
- Male patients who are 40 years of age or older
- Individuals who exhibit increased PSA values (e.g., PSA \>4 ng/mL) or abnormal results on a digital rectal examination (DRE), which are clinical indicators of prostate cancer) 16
Age in the registry: 40 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aznostics The Diagnostic Center Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.